natgillin/translations-raw huggingface dataset:
A urinary fistula has occurred in one case due to incorrect fibre placement.
V enem primeru se je zaradi nepravilne namestitve vlaken pojavila urinska fistula.
Extraprostatic necrosis There may be extraprostatic necrosis in the peri-prostatic fat not associated with clinical symptoms.
Ekstraprostatična nekroza V periprostatični maščobi se lahko pojavi ekstraprostatična nekroza, ki ni povezana s kliničnimi simptomi.
• Information on the existing therapeutic approaches (including VTP with TOOKAD) for the treatment of the type of prostate cancer
• informacije o obstoječih terapevtskih pristopih (vključno o postopku VTP z zdravilom
Current exacerbation of rectal inflammatory bowel disease (see section 4.4).
Trenutno poslabšanje rektalne vnetne črevesne bolezni (glejte poglavje 4.4).
The most frequently reported adverse reactions in the Phase II and III clinical studies were urinary and reproductive system disorders: dysuria (25.1 %), erectile dysfunction (21.1 %), haematuria (19.6 %), perineal pain/haematoma (15.3 %), urinary retention (13.3 %), micturition urgency (9.0 %), pollakiuria (7.3 %), urinary tract infection (5.5 %), incontinence (5.3 %) and ejaculation failure
in III. faze, so bile bolezni ledvic in sečil ter motnje reprodukcije: disurija (25,1 %), erektilna disfunkcija (21,1 %), hematurija (19,6 %), bolečina/hematom v presredku (15,3 %), zadrževanje urina (13,3 %), siljenje na vodo (9,0 %), polakiurija (7,3 %), okužba sečil (5,5 %), inkontinenca (5,3 %) in neuspešna ejakulacija
He should wear dark clothes and take care when exposing hands and face to the sun.
Nositi mora temna oblačila in biti pazljiv pri izpostavljanju rok in obraza soncu.
Transfer the contents of the vial into an opaque syringe.
Vsebino viale prenesite v neprosojno brizgo.
It should only be used by personnel trained in the Vascular-Targeted Photodynamic therapy (VTP) procedure.
Zdravilo lahko uporablja le osebje, ki je usposobljeno za postopek žilno ciljanega fotodinamičnega zdravljenja (VTP -Vascular-Targeted
In case of positive biopsies, patients who exceed the threshold for low risk disease (i.e. have GS > 6, > 3 positive cores or any single core length > 5mm) should receive a treatment recommendation for radical therapy.
Pri pozitivnih biopsijah je treba bolnikom, pri katerih je presežen prag za nizko tvegano bolezen (npr. pri katerih je GS > 6 in pri katerih je število pozitivnih stebričkov > 3 ali pa je dolžina katerega koli posameznega stebrička >5 mm), priporočiti radikalno zdravljenje.
This should be taken into consideration in patients with reduced kidney function or patients on a controlled potassium diet where a rise in serum potassium would be considered detrimental (see section 4.2).
To je treba upoštevati pri bolnikih z okvarjenim delovanjem ledvic ali pri bolnikih, ki so na dieti z nadzorovanim vnosom kalija, pri katerih bi povečanje kalija v serumu veljalo za škodljivo (glejte poglavje 4.2).
c
Z
If the patient reports discomfort to the skin or eyes during hospitalisation, reduce the level of lighting and take extra care to shield the patient from artificial and natural light.
Če bolnik med hospitalizacijo poroča o nelagodnih občutkih na koži ali v očeh, zmanjšajte osvetljenost ter posebej pazite na to, da bolnika zaščitite tako pred umetno kot tudi naravno svetlobo.
However, the short duration of action of TOOKAD means that the risk of enhanced phototoxicity is expected to be low provided these patients strictly follow the precautions against light exposure.
Toda zaradi kratkotrajnega delovanja zdravila TOOKAD naj bi bilo tveganje povečane fototoksičnosti po pričakovanjih nizko, če ti bolniki strogo upoštevajo previdnostne ukrepe izogibanja svetlobi.
Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology and repeated dose toxicity.
Neklinični podatki na osnovi običajnih študij farmakološke varnosti in toksičnosti pri ponavljajočih se odmerkih ne kažejo posebnega tveganja za človeka.
The risk of sphincter damage can be minimised by careful planning of the fibre placement using the treatment guidance software.
Tveganje za poškodbe mišice zapiralke je mogoče zmanjšati s pazljivim načrtovanjem namestitve vlaken s programsko opremo za usmerjanje zdravljenja.
Abnormal clotting is not expected to affect how well the treatment works ; however, it is recommended that drugs that affect clotting are stopped prior to and for the immediate period following the VTP procedure.
Ni pričakovati, da bi nenormalno strjevanje krvi vplivalo na to, kako dobro deluje zdravljenje, vendar zdravil, ki vplivajo na strjevanje, ni priporočljivo jemati pred postopkom VTP in takoj po njem.
Any previous prostatic interventions where the internal urinary sphincter may have been damaged, including trans-urethral resection of the prostate (TURP) for benign prostatic hypertrophy.
Kakršni koli predhodni posegi na prostati, pri katerih bi se lahko poškodovala notranja mišica zapiralka sečnice, vključno s transuretralno resekcijo prostate (TURP - Trans-Urethral Resection of the Prostate) pri benigni hipertrofiji prostate.
There was no significant correlation between the percentage of prostate necrosis on Day 7 MRI and the likelihood of a negative prostate biopsy at follow-up.
Med odstotkom nekroze prostate, ugotovljene z MRI 7. dne, in verjetnostjo negativne biopsije prostate ob kontroli ni bilo pomembne korelacije.
An LDI ≥ 1 appeared to be associated with a greater volume of necrosis on Day 7 MRI and greater share of patients with negative biopsy at 6 months compared with an LDI < 1 (see section 4.2).
Indeks LDI ≥ 1 se je v primerjavi z indeksom LDI < 1 zdel povezan z večjo prostornino nekroze, ugotovljeno z MRI 7. dne, in z večjim deležem bolnikov z negativno biopsijo po 6 mesecih (glejte poglavje 4.2).
The patient can return to normal activity and tolerate direct sunlight 48 hours after the procedure.
Bolnik se lahko vrne k običajnim dejavnostim in prenaša neposredno sončno svetlobo, ko preteče
Pharmacotherapeutic group: Sensitizers used in photodynamic/radiation therapy, ATC code: L01XD07
5.1 Farmakodinamične lastnosti Farmakoterapevtska skupina: zdravila za fotodinamično terapijo in terapijo z obsevanjem z vidnim delom elektromagnetnega valovanja, koda ATC: L01XD07
Radical therapy post VTP procedure
Radikalno zdravljenje po postopku VTP
The TOOKAD-VTP procedure is contraindicated in patients with any previous prostatic interventions where the internal urinary sphincter may have been damaged, including transurethral resection of the prostate (TURP) for benign prostatic hypertrophy (see section 4.3).
Postopek TOOKAD-VTP je kontraindiciran pri bolnikih s kakršnimi koli predhodnimi posegi na prostati, pri katerih je bila notranja mišica zapiralka sečnice morda poškodovana, vključno s transuretralno resekcijo prostate (TURP) zaradi benigne hipertrofije prostate (glejte poglavje 4.3).
As shown in Table 6, in the VTP arm of PCM301 study, erectile function domain scores of the 15-question International Index of Erectile Function (IIEF-15) questionnaire showed a marked decrease, 7 days after the VTP procedure followed by a subsequent improvement in the following months up to Month 24, in the ITT population and in patients meeting the indication criteria.
Kot je prikazano v preglednici 6, so v kraku VTP študije PCM301 rezultati s področja erektilne disfunkcije, pridobljeni iz 15 vprašanj mednarodnega indeksa erektilne funkcije (IIEF-15International Index of Erectile Function), v populaciji ITT in pri bolnikih, ki izpolnjujejo merila indikacije, 7 dni po postopku VTP pokazali jasno zmanjšanje, ki mu je v naslednjih mesecih do 24. meseca sledilo izboljšanje.
There is limited clinical information on overdose involving TOOKAD.
O prevelikem odmerjanju v povezavi z zdravilom TOOKAD obstajajo omejene informacije.
You or your partner or both should use an effective form of birth control to prevent your partner getting pregnant for 90 days after the VTP procedure.
Da preprečite zanositev partnerke, morate vi ali vaša partnerka ali pa oba 90 dni po postopku VTP uporabljati učinkovito obliko kontracepcije.
Effects of covariates on pharmacokinetic properties The effects of age, weight and race were investigated in healthy volunteers and patients.
Pri zdravih prostovoljcih in bolnikih so bili preučevani vplivi starosti, mase in rase.
Moderate/higher risk prostate cancer was defined as any of the following: > 3 cores definitively positive for cancer; Gleason primary or secondary pattern ≥ 4; at least 1 cancer core length > 5 mm; PSA > 10 ng/mL in 3 consecutive measures; T3 prostate cancer; metastasis; prostate cancer-related death.
Zmerno/visoko tvegani rak prostate je bil opredeljen kot kar koli od naslednjega: > 3 stebrički, ki so zagotovo pozitivni za raka; primarni ali sekundarni vzorec po Gleasonu ≥ 4; vsaj 1 dolžina stebrička rakastega tkiva > 5 mm; PSA > 10 ng/ml pri treh zaporednih meritvah; rak prostate T3; metastaza; smrt, povezana z rakom prostate.
There is no relevant use of TOOKAD in the paediatric population in the treatment of low-risk localised prostate cancer.
Uporabe zdravila TOOKAD za zdravljenje nizko tveganega raka prostate pri pediatrični populaciji ni relevantna.
Anticoagulants and antiplatelet agents
Antikoagulanti in antitrombotiki
This should be taken into consideration by patients with reduced kidney function or patients on a controlled potassium diet where a rise in serum potassium would be considered detrimental.
To je treba upoštevati pri bolnikih z okvarjenim delovanjem ledvic ali bolnikih, ki so na dieti z nadzorovanim vnosom kalija, pri katerih bi povečanje kalija v serumu lahko bilo škodljivo.
In assessing overall tolerability by Month 24, post enrolment patients who underwent a radical therapy were also counted in the scoring of prostate symptoms and erectile function.
Pri ocenjevanju splošnega prenašanja do 24. meseca so bili v ocenjevanje simptomov prostate in erektilne funkcije všteti tudi bolniki po vključitvi v študijo, ki so bili zdravljeni radikalno.
Minimal metabolism of padeliporfin was observed in in vitro metabolism studies in human liver microsomes and S9 fractions.
V študijah presnove in vitro v humanih jetrnih mikrosomih in frakcijah S9 je bila opažena minimalna presnova padeliporfina.
The patient may go outdoors during daylight hours but only in shaded areas or when it is overcast.
Bolnik se lahko podnevi zadržuje zunaj, vendar le v senci ali takrat, ko je oblačno.
In healthy human male subjects, the Cmax was shown to be linear from 1.25 mg/kg to 15 mg/kg of padeliporfin di-potassium, covering the therapeutic range.
Pri zdravih moških je bilo dokazano, da je vrednost Cmax linearna od 1,25 mg/kg do 15 mg/kg dikalijevega padeliporfina, kar zajema terapevtski razpon.
Its volume is measured after prostate delineation using the treatment guidance software.
Njegova prostornina se izmeri po zamejitvi prostate s programsko opremo za usmerjanje zdravljenja.
PHARMACEUTICAL FORM AND CONTENTS Powder for solution for injection
FARMACEVTSKA OBLIKA IN VSEBINA prašek za raztopino za injiciranje
If it is not possible to stop a photosensitising medicine (such as amiodarone), increased sensitivity may occur, you may need to protect yourself from direct light exposure for a longer period.
Če prenehanje uporabe zdravil, ki povzročajo preobčutljivost na svetlobo (kot je amiodaron), ni mogoče, lahko pride do povečane občutljivosti in morda se boste morali dlje časa varovati pred izpostavljenostjo neposredni svetlobi.
MARKETING AUTHORISATION NUMBER(S) EU/1/17/1228/001
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/17/1228/001
Number of subjects who initiated a radical treatment after progression, n (%)
Število oseb, ki je začelo radikalno zdravljenje po napredovanju bolezni, n (%)
MARKETING AUTHORISATION NUMBER(S) EU/1/17/1228/002
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/17/1228/002
The patient should wear protective goggles and be kept under medical surveillance for at least 6 hours in a room with dimmed light.
Bolnik mora nositi zaščitna očala in biti pod zdravniškim nadzorom v sobi s pridušeno svetlobo vsaj
See also under “Other medicines and TOOKAD” for the effects of anticoagulants and antiplatelet medicines.
Vplive antikoagulantov in antitrombotikov si oglejte tudi v poglavju „Druga zdravila in zdravilo TOOKAD“.
Medicinal products which have potential photosensitising effects (such as tetracyclines, sulphonamides, quinolones, phenothiazines, sulfonylurea hypoglycaemic agents, thiazide diuretics, griseofulvin or amiodarone) should be stopped at least 10 days before the procedure with TOOKAD and for at least 3 days after the procedure or replaced by other treatments without photosensitizing properties.
Zdravila, ki povzročajo preobčutljivost na svetlobo Z uporabo zdravil, ki lahko povzročajo preobčutljivost na svetlobo (kot so tetraciklini, sulfonamidi, kinoloni, fenotiazini, sulfonilsečninske hipoglikemične učinkovine, tiazidni diuretiki, griseofulvin ali amiodaron), je treba prenehati vsaj 10 dni pred postopkom z zdravilom TOOKAD in jih ne uporabljati vsaj 3 dni po postopku ali pa jih zamenjati z drugimi zdravljenji, ki ne povzročajo preobčutljivosti na svetlobo.
This required urethral dilatation (see section 4.4).
Posledično je bila potrebna dilatacija sečnice (glejte poglavje 4.4).
The chemical and physical stability of TOOKAD after reconstitution with 5 % glucose solution, in its vial, has been demonstrated for 8 hours at 15°C-25°C and at 5°C ± 3°C.
Kemijsko in fizikalno stabilnost zdravila TOOKAD po rekonstituciji s 5-odstotno raztopino glukoze v viali, v kateri je zdravilo, so dokazali za 8 ur pri 15-25 °C in pri 5 °C ± 3 °C.
During the procedure, the optical fibres are selected and positioned transperineally into the prostate gland under ultrasound guidance to achieve a Light Density Index (LDI) ≥ 1 in the targeted tissue.
Med postopkom so optična vlakna izbrana in z ultrazvočnim vodenjem transperinealno nameščena v prostato, da je v ciljanem tkivu dosežen indeks gostote svetlobe (LDI) ≥ 1.
This includes sunbeds, bright computer monitor screens and medical examination lights, such as ophthalmoscopes, otoscopes and endoscopy equipment, for 48 hours following the VTP procedure.
To v 48 urah po postopku VTP vključuje solarije, bleščeče računalniške zaslone in luči za medicinske preiskave, kot so oftalmoskopi, otoskopi in oprema za endoskopijo.
If you have a history of a narrowing of the urethra or urinary flow problems, treatment may increase the risk of poor flow and urinary retention.
Težave, povezane s sečnico Če imate anamnezo zoženja sečnice ali težave s pretokom urina, lahko zdravljenje poveča tveganje slabega pretoka in zastajanja urina.
One case of external urethral fistula occurred due to fibre misplacement (see section 4.4).
Do enega primera zunanje fistule sečnice je prišlo zaradi nepravilne namestitve vlaken (glejte poglavje 4.4).
Short-term urinary incontinence has been observed and may result from urinary tract infection or from urgency caused by irritation to the urethra from the procedure.
Opazili so kratkotrajno urinsko inkontinenco, ki jo lahko povzroča okužba sečil ali siljenje na vodo zaradi draženja sečnice, ki ga povzroča postopek.
After reconstitution with a 5 % glucose solution in its vial, the chemical and physical stability of TOOKAD has been demonstrated for 8 hours at 15°C-25°C and at 5°C ± 3°C.
Po rekonstituciji zdravila TOOKAD s 5-odstotno raztopino glukoze v viali, v kateri je zdravilo, je bila kemijska in fizikalna stabilnost dokazana za 8 ur pri temperaturi 15-25 °C in za 5 °C ± 3 °C.
Post-authorisation efficacy study (PAES): In order to further investigate long-term efficacy of TOOKAD and its impact on disease progression including potential impact on the efficacy of subsequent radical therapy in patients with low risk prostate cancer as well as further characterise the long term safety of TOOKAD, the MAH should submit the results of a randomised phase 3 study in patients with localised prostate cancer compared to active surveillance (7-year follow-up study including in an depth biopsy study) (PCM301 FU5).
Študija učinkovitosti zdravila po pridobitvi dovoljenja za promet z zdravilom (PAES): Za dodatno proučitev dolgoročne učinkovitosti zdravila TOOKAD in njegovega vpliva na napredovanje bolezni, vključno z morebitnim vplivom na učinkovitost naknadnega radikalnega zdravljenja pri bolnikih z nizko tveganim rakom prostate, in dodatno opredelitev dolgoročne varnosti zdravila TOOKAD mora imetnik dovoljenja za promet z zdravilom predložiti randomizirano študijo III. faze bolnikov z lokaliziranim rakom prostate v primerjavi z aktivnim opazovanjem (sedemletno kontrolno študijo, vključno s poglobljeno biopsijsko študijo) (PCM301
Blood lactate dehydrogenase increased Blood triglyceride increased Gamma-glutamyltransferase increased Blood cholesterol increased Blood creatine phosphokinase increased Blood potassium decreased Low density lipoprotein increased Neutrophil count increased PSA increased
občasni zvišana raven laktat-dehidrogenaze v krvi zvišana raven trigliceridov v krvi zvišana raven gama-glutamiltransferaze zvišana raven holesterola v krvi zvišana raven kreatin-fosfokinaze v krvi znižana raven kalija v krvi zvišana raven lipoproteina nizke gostote zvečano število nevtrofilcev zvišana raven PSA zmanjšana telesna masa zvečano število belih krvnih celic
This medicinal product contains potassium and in general the dose (3.66 mg/kg) will be less than 1 mmol (39 mg) i.e. essentially ‘potassium free'.
Uporaba pri bolnikih, ki so na dieti z nadzorovanim vnosom kalija To zdravilo vsebuje kalij in v splošnem bo odmerek (3,66 mg/kg) manjši od 1 mmol (39 mg), tj. pravzaprav „brez kalija“.
The median time to onset of urinary retention was 3 days (1-417).
Srednja vrednost časa do nastopa zastajanja urina je znašala 3 dni (1-417).
Male sexual dysfunction (erectile dysfunction, ejaculation failure, dyspareunia, ejaculation disorder, hypospermia, painful ejaculation, retrograde ejaculation, sexual dysfunction, semen volume decreased).
10 Motnje spolnosti pri moških (erektilna disfunkcija, neuspešna ejakulacija, dispareunija, motnje ejakulacije, hipospermija, boleča ejakulacija, retrogradna ejakulacija, motnje spolnosti, zmanjšanje količine semena).
If you have had an active inflammatory bowel disease or any condition that may increase the risk of causing abnormal connection between the rectum and the urethra (recto-urethral fistula), the treatment should be given only after careful evaluation.
Aktivna vnetna črevesna bolezen Če je bila pri vas prisotna aktivna vnetna črevesna bolezen ali kakršno koli stanje, ki lahko poveča tveganje za nastanek nenormalne povezave med danko in sečnico (rektouretralna fistula), lahko zdravljenje prejemate le po skrbni presoji.
Planning of optical fibre positioning should be performed at the beginning of the procedure using the treatment guidance software.
Položaj optičnih vlaken je treba s programsko opremo za usmerjanje zdravljenja nastaviti na začetku postopka.
You must remain under reduced light conditions, without exposing your skin and your eyes to daylight.
Ostati morate v okolju s pridušeno svetlobo, kože in oči pa ne smete izpostavljati dnevni svetlobi.
AS arm N = 78
Krak AS N = 78
The LDI corresponds to the ratio of the cumulative length of illuminated fibre tips (cm) to the volume (cc) of the targeted zone to be treated.
Indeks LDI ustreza razmerju med kumulativno dolžino osvetljenih konic vlaken (v cm) in prostornino (v cc)
The main inclusion criteria were low-risk prostate cancer with Gleason 3 + 3 prostate adenocarcinoma as a maximum, two to three cores positive for cancer and a maximum cancer core length of 5 mm in any core (at least 3 mm for patients with only one positive core), clinical stage up to T2a, PSA ≤ 10 ng/mL, prostate volume equal or greater than 25 cc and less than 70 cc.
Glavna merila za vključitev so bila nizko tvegani rak prostate z največ adenokarcinomom prostate z oceno po Gleasonu 3 + 3, od dva do trije stebrički, pozitivni za raka, in največja dolžina stebrička rakastega tkiva 5 mm v katerem koli stebričku (vsaj 3 mm za bolnike s samo enim pozitivnim stebričkom), klinični stadij do T2a, PSA ≤ 10 ng/ml ter prostornina prostate enaka ali večja od 25 cc in manjša od 70 cc.
In healthy human male subjects, the mean volume of distribution ranged from 0.064-0.279 L/kg, for posologies from 1.25 to 15 mg/kg of padeliporfin di-potassium indicating distribution into extracellular fluid.
Pri zdravih moških se je srednja vrednost prostornine porazdelitve gibala od 0,064 do 0,279 l/kg pri odmerjanju od 1,25 do 15 mg/kg dikalijevega padeliporfina, kar kaže porazdelitev v zunajcelično tekočino.
The educational programme is aimed at increasing awareness and providing information concerning the signs and symptoms of certain important identified risks of padeliporfin, including photosensitivity, and also information on the existing therapeutic approaches (including VTP with
Izobraževalni program je namenjen povečevanju ozaveščenosti in zagotavljanju informacij v zvezi z znaki in simptomi določenih pomembnih znanih tveganj padeliporfina, vključno s preobčutljivostjo na svetlobo, pa tudi informacijami o obstoječih terapevtskih pristopih (vključno s postopkom VTP z zdravilom TOOKAD) za zdravljenje določene vrste raka prostate ter morebitnih koristih, tveganjih in negotovostih postopka VTP z zdravilom TOOKAD.
Table 3 describes the co-primary efficacy endpoints in the whole prostate gland and in the treated lobe (ITT population and patients meeting the indication criteria).
V preglednici 3 so opisani sočasni primarni opazovani dogodki učinkovitosti v celotni prostati in zdravljenem režnju (pri populaciji ITT in bolnikih, ki izpolnjujejo merila indikacije).
In vitro studies predict that TOOKAD at therapeutic concentrations is unlikely to inhibit cytochrome P450 enzymes but could inhibit OATP1B1 and OATP1B3 transporters (see section 5.2).
Študije in vitro napovedujejo, da za zdravilo TOOKAD v terapevtskih koncentracijah ni verjetno, da bi zaviralo encime citokroma P450, lahko pa bi zaviralo prenašalce OATP1B1 in OATP1B3 (glejte poglavje 5.2).
Padeliporfin was shown to be cytotoxic in the presence of UVA irradiation (in vitro) and considered phototoxic in the guinea pig (in vivo).
Dokazali so, da je padeliporfin citotoksičen v prisotnosti obsevanja s svetlobo UVA (in vitro), pri morskih prašičkih pa velja za fototoksičnega (in vivo).
Unspecific adverse events probably linked to the general anaesthesia were also observed: transient global amnesia, bradycardia, sinus arrhythmia, atrial fibrillation, hypotension, bronchospasm, pharyngeal inflammation, respiratory tract congestion, nausea, vomiting, constipation, pyrexia, procedural hypotension.
Opazili so tudi nespecifične neželene učinke, ki so verjetno povezani s splošno anestezijo: prehodno globalno amnezijo, bradikardijo, sinusno aritmijo, atrijsko fibrilacijo, hipotenzijo, bronhospazem,
Abnormal clotting (fibrin D dimer increased, aPTT prolonged, INR increased).
14 Nenormalno strjevanje krvi (povečan D-dimer fibrina, podaljšan aPTT, povečan INR).
In vitro genotoxicity testing identified padeliporfin as having weak potential to induce clastogenicity when illuminated by ultraviolet (UV); this correlates with the mechanism of action (formation of reactive oxygen species).
S testiranjem genotoksičnosti in vitro so ugotovili, da ima padeliporfin šibko sposobnost sprožanja klastogenosti, če je osvetljen z ultravijolično (UV) svetlobo; to ustreza mehanizmu delovanja
Carcinogenicity and reproductive toxicity studies have not been conducted with padeliporfin.
Študije kancerogenosti in vpliva na sposobnost razmnoževanja padeliporfina niso bile izvedene.
How TOOKAD is used
Kako uporabljati zdravilo TOOKAD
Fibres to carry the laser light are inserted into the prostate gland by using hollow needles.
Vlakna, ki prevajajo lasersko svetlobo, so z votlimi iglami vstavljena v prostato.